Eligibility for pharmacological therapies in heart failure with reduced ejection fraction: implications of the new Chronic Kidney Disease Epidemiology Collaboration creatinine equation for estimating glomerular filtration rate

• Published in: European journal of heart failure 2022-05, Vol.24 (5), p.861-866
• Main Authors: Butt, Jawad H., Adamson, Carly, Docherty, Kieran F., Vaduganathan, Muthiah, Solomon, Scott D., Anand, Inder S., Zannad, Faiez, Køber, Lars, Jhund, Pardeep S., McMurray, John J.V.
• Format: Article
• Language: English
• Subjects: Cardiology and cardiovascular system; Creatinine; Female; Glomerular Filtration Rate; Heart Failure - drug therapy; Heart Failure - epidemiology; Human health and pathology; Humans; Life Sciences; Male; Middle Aged; Renal Insufficiency, Chronic - drug therapy; Renal Insufficiency, Chronic - epidemiology; Stroke Volume
• ISSN: 1388-9842; 1879-0844; 1879-0844
• DOI: 10.1002/ejhf.2460

Aims The new Chronic Kidney Disease Epidemiology Collaboration (CKD‐EPI) equation for estimating glomerular filtration rate (eGFR), based on serum creatinine, that does not incorporate race may reclassify individuals, irrespective of race, from one eGFR category to another, with implications for eligibility for treatments in patients with heart failure and reduced ejection fraction (HFrEF). Methods and results A total of 43 138 ambulatory patients with HFrEF from 12 clinical trials were included (mean age 64.3 years; 9580 [22.2%] women). Mean eGFR was 67 (standard deviation [SD] 21) ml/min/1.73 m2 and 70 (SD 21) ml/min/1.73 m2 using the original and new CKD‐EPI equations, respectively (mean difference 3.20 ml/min/1.73 m2, 95% confidence interval [CI] 3.17–3.23, p